Vasoactive intestinal polypeptide precursors have highly potent bronchodilatory activity

Area of Science:

• Biochemistry
• Pharmacology
• Peptide Chemistry

Background:

• Vasoactive intestinal polypeptide (VIP) is a crucial neuropeptide with diverse physiological roles.
• Understanding VIP's structure-activity relationships is key to developing novel therapeutic agents.
• Investigating C-terminal modifications may reveal enhanced biological activities.

Purpose of the Study:

• To elucidate the structure-activity relationships of vasoactive intestinal polypeptide (VIP).
• To identify potentially active C-terminal-free VIP forms for recombinant production.
• To evaluate the biological activity of modified VIP precursors.

Main Methods:

• Solid-phase synthesis of presumptive VIP precursors.
• In vitro and in vivo assessment of biological activities.
• Comparative analysis of modified peptides versus natural VIP.

Main Results:

• Certain VIP precursors synthesized via solid-phase methods displayed superior biological activity compared to natural VIP.
• VIP-Gly-Lys-OH and VIP-Gly-Lys-Arg-OH exhibited significantly increased bronchodilatory effects (210% and 160%, respectively).
• These modified peptides also demonstrated enhanced hypotensive activity (110% and 130% increase, respectively).

Conclusions:

• Modified VIP structures, particularly C-terminal extensions, possess enhanced bronchodilatory and hypotensive properties.
• These findings suggest the potential for developing more potent VIP analogs through recombinant technology.
• Further research is warranted to identify the precise active fragments and optimize these modified peptides for therapeutic applications.